en
Scientific article
English

Live vaccines and immunosuppressive monoclonal antibodies: weighing up the benefit-risk assessment for natalizumab

Published inJournal of Travel Medicine, vol. 28, no. 3, taaa235
Publication date2021
Abstract

We consider the safety of live vaccines when used in patients on natalizumab, a long-acting immunosuppressive monoclonal antibody. Based on this drug's specific mode of action we propose a benefit/risk assessment on a case-by-case basis with individual considerations, rather than a generic contra-indication.

Keywords
  • Antibodies, Monoclonal/adverse effects
  • Antibodies, Monoclonal/therapeutic use
  • Humans
  • Immunosuppressive Agents/adverse effects
  • Immunosuppressive Agents/therapeutic use
  • Natalizumab/adverse effects
  • Natalizumab/therapeutic use
  • Risk Assessment
  • Vaccines, Attenuated/adverse effects
  • Vaccines, Attenuated/therapeutic use
  • Multiple sclerosis
  • Measles
  • Yellow fever
  • Immunosuppressive/immunomodulating (ISIM) medications
  • Immunosuppression,immunization
Citation (ISO format)
SCHWOB, Jean-Marc et al. Live vaccines and immunosuppressive monoclonal antibodies: weighing up the benefit-risk assessment for natalizumab. In: Journal of Travel Medicine, 2021, vol. 28, n° 3, p. taaa235. doi: 10.1093/jtm/taaa235
Main files (1)
Article (Published version)
accessLevelRestricted
Identifiers
ISSN of the journal1195-1982
155views
0downloads

Technical informations

Creation03/02/2021 2:14:00 PM
First validation03/02/2021 2:14:00 PM
Update time03/16/2023 12:47:27 AM
Status update03/16/2023 12:47:26 AM
Last indexation01/17/2024 1:33:13 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack